glp 1 for cardiovascular The effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Semaglutide Shows Secondary Cardiovascular Prevention
Description
Obesity has escalated into a global epidemic, with over 1 billion individuals affected worldwide, including nearly 880 million adults and 159 million children and adolescents aged 519 years (World Obesity Federation)
You are not alone
Struggling with GLP-1 therapy side effects
With the emergence of GLP-1s, there is a divide between patient perception of the medication and how clinical science views it
Discover proper techniques for current injectable GLP-1 medications and what to know about future transdermal delivery systems.
